Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Down 5% – Here’s What Happened

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) traded down 5% on Wednesday . The stock traded as low as $9.6017 and last traded at $9.6026. 6,325 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 96,967 shares. The stock had previously closed at $10.1080.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Zacks Research downgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.9%

The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $16.38 billion, a P/E ratio of 12.67, a P/E/G ratio of 0.75 and a beta of 0.19. The stock’s 50 day simple moving average is $10.98 and its 200 day simple moving average is $9.62.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its earnings results on Friday, January 30th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.09. The company had revenue of $966.53 million for the quarter, compared to analysts’ expectations of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. As a group, research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.73 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.